Boehringer Ingelheim Venture

The Boehringer Ingelheim Venture Fund (BIVF) is a €350 million evergreen corporate venture fund of Boehringer Ingelheim, one of the world's largest family-owned pharmaceutical companies. Founded in 2010 and headquartered in Ingelheim am Rhein, Germany, with additional offices in the United States and China, BIVF invests in groundbreaking, therapeutics-focused biotechnology companies to drive innovation in biomedical research. The fund's capital base has grown substantially since inception, more than doubling through successive expansions that reflect Boehringer Ingelheim's deepening commitment to external innovation. BIVF leads rounds from seed through Series B, deploying checks between $3 million and $30 million, and has built a portfolio of over 40 companies with 6 exits back to the Boehringer Ingelheim parent. The fund's scientific focus spans first-in-class, disease-modifying therapeutics across immuno-oncology, regenerative medicine, infectious diseases, and digital health. The investment thesis prioritizes unprecedented therapeutic concepts addressing high medical need rather than incremental improvements on existing mechanisms. BIVF's evergreen structure distinguishes it from fund-cycle-constrained investors, allowing it to support portfolio companies across the extended development timelines that novel therapeutics require. The fund's global presence across Europe, the US, and China enables it to source and support biotechnology innovation wherever it originates. Portfolio companies benefit from Boehringer Ingelheim's deep expertise in clinical development, regulatory affairs, and pharmaceutical manufacturing — resources that can meaningfully accelerate the translation of early science into approvable therapies.